News​

​CAM Bioceramics and Ossiform team up for OMTEC 2022

As partners through several years, Ossiform, the developer of proprietary technology to produce natural, patient specific, and resorbable bone implants, and CAM Bioceramics, a leading contract development and manufacturing company of Orthobiologic Calcium Phosphates, have teamed up to showcase their service and product portfolios at OMTEC 2022.

Ossiform – New market-oriented Chairman of the Board

​ODENSE, 1st June 2021 – Ossiform, We Print Bone™, is pleased to announce that a new and highly qualified Chairman of the Board has been found.

​

The Company appoints Mette-Marie Harild as new Chairman of the Board if she is elected to the board of directors at Ossiform Limited’s general meeting which will take place on 15th June 2021.

Big step towards market approval and registration: Ossiform initiates QMS implementation

December 11th, 2020, Ossiform's executive management signed the first fundamental procedures of the Quality Management System which will lay the foundation for the market approval and registration of the P3D Bone implant in the USA.

​

The Company has thereby commenced the implementation of a medical device Quality Management System with a view to achieve ISO 13485 certification – the international standard for quality management systems in the medical device industry. 

New research paper: Treating mouse skull defects with 3D-printed fatty acid and tricalcium phosphate implants

View the results of the new peer-reviewed paper on the performance of P3D Bone as a novel form of individualized ceramic bone implants.​

Patent for Ossiform’s technology granted in the USA

June 9th 2020, the United States Patent and Trademark office (USPTO) announced that Ossiform’s patent, Feedstock for 3D printing and uses thereof no. PCT/DK2016/050323, has been granted in the USA.

​

This marks Ossiform’s second patent issuance, following the approval and publication of its European patent, EP/3359318, in April 2020.​

Ossiform raises capital through West Hill

ODENSE, May 18th, 2020 – Ossiform, We Print Bone™, is pleased to announce that the £2.5 million capital raise through West Hill Capital was heavily oversubscribed. Ossiform has developed a disruptive and patented technology to be used to produce and supply P3D Bone; 3D printed patient-specific, resorbable bone implants that remodel into real living bone. The first research products have been launched, the P3D Scaffolds, bringing natural bone environments into laboratories.​

Ossiform enters U.S. partnership with Asimov Ventures

Ossiform receives investment from New York based venture capital firm, Asimov Ventures, and enters valuable U.S. partnership. The partnership with Asimov Ventures marks the Company’s first step into the U.S. market, looking toward an early commercialization of P3D Bone in the USA.​